Phase 2 Lung Cancer Trial, Not Yet Recruiting NCT06336954 Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Not Yet Recruiting

NCT06336954
Not Yet Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years old or older and willing to sign a consent form agreeing to take part.
  • You should be generally well enough to carry out light activity or daily tasks (not severely limited by illness).
  • You must have been diagnosed with advanced lung cancer (stage IIIB or IV, non-small cell type) that has continued to grow or spread after treatment with a type of immunotherapy called a PD-1 inhibitor.
  • Doctors must expect you to live for at least 3 months, and you must have at least one area of cancer that can be measured on a scan.
  • Your blood counts, liver, kidney, and blood clotting test results must meet certain levels set by the trial (confirm specific values with trial site).
  • If you have had cancer spread to the brain, it must have been treated and be considered stable.
  • If you could become pregnant, or if your partner could become pregnant, you must agree to use contraception during the trial.

Who may not be able to join:

  • You have previously received certain other types of immunotherapy or specific cancer treatments (confirm which treatments apply with the trial site).
  • You have certain types of cancer, specific gene mutations, or have recently taken steroid medications or drugs that suppress the immune system.
  • You have brain or spinal fluid cancer spread that has not been treated or is not yet stable, a recent serious infection, or have had major surgery recently.
  • You have other health conditions that could interfere with the trial, such as uncontrolled fluid build-up in body cavities, active autoimmune disease, significant bleeding or blood clotting problems, serious heart conditions, severe allergies to the trial drugs, another active cancer, HIV/AIDS, hepatitis B or C, or are currently taking part in another clinical trial (confirm timeframes with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Second Affiliated Hospital of Xi'an Jiaotong University
Registry
ClinicalTrials.gov
Start date
30 March 2024
Est. completion
31 July 2024

Primary endpoints

Progression-free survival time (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov